Evidence map›Paper›PMID 37937259›Full record

ArticleJournal of medical imaging (Bellingham, Wash.)2023

Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation of

Joint Head and Neck Radiotherapy-MRI Development Cooperative, Travis C Salzillo, M Alex Dresner, Ashley Way, Kareem A Wahid, Brigid A McDonald, Sam Mulder, Mohamed A Naser, Renjie He, Yao Ding and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical imaging (Bellingham, Wash.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Joint Head and Neck Radiotherapy-MRI Development Cooperative
Travis C SalzilloMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.ORCID https://orcid.org/0000-0001-6271-9879
M Alex DresnerPhilips Healthcare, Cleveland, Ohio, United States.
Ashley WayMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Kareem A WahidMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.ORCID https://orcid.org/0000-0002-0503-0175
Brigid A McDonaldMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Sam MulderMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Mohamed A NaserMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Renjie HeMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Yao DingMD Anderson Cancer Center, Radiation Physics, Houston, Texas, United States.
Alison YoderMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.ORCID https://orcid.org/0000-0002-2606-3814
Sara AhmedMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Kelsey L CorriganMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Gohar S ManzarMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Lauren AndringMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
Chelsea PinnixMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
R Jason StaffordMD Anderson Cancer Center, Imaging Physics, Houston, Texas, United States.
Abdallah S R MohamedMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.
John ChristodouleasElekta AB, Stockholm, Sweden.
Jihong WangMD Anderson Cancer Center, Radiation Physics, Houston, Texas, United States.
Clifton David FullerMD Anderson Cancer Center, Radiation Oncology, Houston, Texas, United States.ORCID https://orcid.org/0000-0002-5264-3994
The University of Texas MD Anderson Cancer Center · USElekta (Sweden) · SEPhilips (United States) · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac deviceR01DE028290 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTODOULEAS, JOHN PAUL, FULLER, CLIFTON DAVID · 2019 to 2023
$4.3M
NRSA Training CoreTL1TR003169 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANDRA, JOYA, FROST, JEFFREY A. · 2019 to 2023
$3.7M
Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Establish Objective Clinical Outcome Measures for Mandibular OsteoradionecrosisR01DE025248 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LAI, STEPHEN Y · 2016 to 2020
$2.9M
Image Guided Cancer Therapy Training ProgramT32CA261856 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kristy Brock, Clifton David Fuller · 2022 to 2026
$1.2M
imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FULLER, CLIFTON DAVID, HUTCHESON, KATHERINE ARNOLD · 2017 to 2019
$810k
Fellow and Resident Radiation Oncology iNtensive Training in Imaging and Informatics to Empower Research Careers (FRONTI2ER)R25EB025787 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAS, PRAJNAN, FULLER, CLIFTON DAVID · 2018 to 2022
$535k
Diffusion-Weighted Imaging-Based Adaptive Replanning for the MR-LinacF31DE029093 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCDONALD, BRIGID ANNE · 2019 to 2021
$91k
Multiparametric Magnetic Resonance Imaging Artificial Intelligence Pipeline for Oropharyngeal Cancer Radiotherapy Treatment GuidanceF31DE031502 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WAHID, KAREEM · 2021 to 2023
$68k
NCATS NIH HHS TL1 TR003169NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA218148NCI NIH HHS T32 CA261856NIBIB NIH HHS R25 EB025787NIDCR NIH HHS F31 DE029093NIDCR NIH HHS F31 DE031502NIDCR NIH HHS R01 DE025248NIDCR NIH HHS R01 DE028290
6 · The paper itself

Abstract

Purpose: To improve segmentation accuracy in head and neck cancer (HNC) radiotherapy treatment planning for the 1.5T hybrid magnetic resonance imaging/linear accelerator (MR-Linac), three-dimensional (3D), T2-weighted, fat-suppressed magnetic resonance imaging sequences were developed and optimized. Approach: After initial testing, spectral attenuated inversion recovery (SPAIR) was chosen as the fat suppression technique. Five candidate SPAIR sequences and a nonsuppressed, T2-weighted sequence were acquired for five HNC patients using a 1.5T MR-Linac. MR physicists identified persistent artifacts in two of the SPAIR sequences, so the remaining three SPAIR sequences were further analyzed. The gross primary tumor volume, metastatic lymph nodes, parotid glands, and pterygoid muscles were delineated using five segmentors. A robust image quality analysis platform was developed to objectively score the SPAIR sequences on the basis of qualitative and quantitative metrics. Results: Sequences were analyzed for the signal-to-noise ratio and the contrast-to-noise ratio and compared with fat and muscle, conspicuity, pairwise distance metrics, and segmentor assessments. In this analysis, the nonsuppressed sequence was inferior to each of the SPAIR sequences for the primary tumor, lymph nodes, and parotid glands, but it was superior for the pterygoid muscles. The SPAIR sequence that received the highest combined score among the analysis categories was recommended to Unity MR-Linac users for HNC radiotherapy treatment planning. Conclusions: Our study led to two developments: an optimized, 3D, T2-weighted, fat-suppressed sequence that can be disseminated to Unity MR-Linac users and a robust image quality analysis pathway that can be used to objectively score SPAIR sequences and can be customized and generalized to any image quality optimization protocol. Improved segmentation accuracy with the proposed SPAIR sequence will potentially lead to improved treatment outcomes and reduced toxicity for patients by maximizing the target coverage and minimizing the radiation exposure of organs at risk.

Indexed as

fat suppressionhead and neck cancermagnetic resonance imaging/linear accelerator

Identifiers

PMID37937259
PMCPMC10627232
OpenAlexW4388424794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.